Artificial intelligence continues to reshape biotech R&D with notable advancements in genome editing, microprotein discovery, and clinical trial recruitment. Profluent, backed by AI, designed a programmable gene editor with enhanced precision surpassing natural CRISPR proteins, potentially democratizing genome engineering. Parallel efforts at the Salk Institute developed ShortStop, a machine learning tool uncovering previously undetectable microproteins from noncoding DNA, highlighting novel therapeutic targets. Additionally, UT Southwestern demonstrated that large language models can streamline identification of clinical trial candidates, improving efficiency. These innovative applications of AI promise to accelerate scientific discovery and therapeutic development across multiple fronts.